INTRODUCTION {#S1}
============

β-lactamases enzyme are one of the major mechanism of resistance to β-lactam antibiotics in many Gram negative bacilli such as *Escherichia coli, Acinetobacter baumannii* and *Pseudomona aeruginosa* ([@R1],[@R2]). AmpC-β-lactamases are the main causes of resistance to β-lactams antibiotics such as extended spectrum cephalosporins, cephamycins, monobactams and carbapenems. Two features differentiate AmpC-β-lactamases from other β-lactamases such as Extended-Spectrum β-lactamases (ESBLs): their resistance to ESBLs inhibitors such as clavulanate and their ability to hydolyze cephamycins such as cefoxitin and cefotetan ([@R4],[@R5]). *P. aeruginosa* is a Gram-negative bacterium that is responsible for severe nosocomial infections among patients with severe burns ([@R3]). AmpC in *P. aeroginosa* usually are encoded by the chromosomal genes and expressed constitutively at a low level ([@R4]). Mutations in *ampC* may lead to overproduction of AmpC-β-lactamases by some *P. aeroginosa* isolates ([@R4]). AmpC overproduction not only causes resistance to cephalosporins, cephamycin and monobactams but also is responsible for resistance to carbapenems ([@R1],[@R4]). *P. aeruginosa* has emerged as important pathogen in Iran as in other countries, which presents serious challenges for hospital infection control practitioners and clinicians treating infected patients ([@R6],[@R7]). There are several reports on the prevalence of MBLs and ESBLs among *P. aeruginosa* isolates in Iran, but the prevalence of AmpC overproduction isolates is unknown ([@R8]-[@R10]). The aim of this study was to detect the AmpC-β-lactamases producer isolates among carbapenem resistant *P. aeruginosa* isolated from burn patient.

MATERIALS AND METHODS {#S2}
=====================

Bacterial strains {#S3}
-----------------

We collected 100 nonconsecutive and non-duplicate of carbapenem resistant *P. aeruginosa* isolates from different burn patients admitted at Shahid Motahari Burn Hospital in Tehran during 2011 and 2012. The isolates were identified by their cultural characteristics and reactions to standard biochemical tests.

Antimicrobial susceptibility testing {#S4}
------------------------------------

The β-lactam antibiotic resistance pattern of isolates was determined by using disk diffusion method according to the Clinical and Laboratory Standard Institute (CLSI) guidelines ([@R11]). The antibiotics were meropenem (MEM) (10μg), imipenem (IMI) (10μg), ertapenem (ETP) (10μg), cefotaxime (CTX) (30μg), ceftazidime (CAZ) (30μg), cefepime (CPM) (30μg) and cefoxitin (FOX) (30μg). All antibiotic disks were prepared form MAST Corporation (UK). *Escherichia coli* ATCC 25922, *Pseudomonas aeroginosa* ATCC 27853 and *Klebsiella pneumoniae* 700603 were used as a quality control strain for antimicrobial susceptibility test.

Detection of AmpC phenotype by phenylboronic acid {#S5}
-------------------------------------------------

Detection of AmpC producer isolates by phenylboronic was performed as described by Song *et al.* ([@R12]). Briefly, disks cefoxitin (FOX, 30μg), cefotaxime (CTX, 30μg), ceftazidime (CAZ, 30μg) and cefepime (CPM, 30μg) alone and in combination with 400 μg phenylboronic acid (BA) were placed on the inoculated surface of the Mueller Hinton agar plate. Then the plates were incubated overnight at 37°C in ambient air. An increase of ≥5 mm in zone diameter of FOX, CAZ, CTX and CPM tested in combination with BA versus FOX, CAZ, CTX and CPM were considered as AmpC positive.

Detection of AmpC phenotype with the AmpC disk test {#S6}
---------------------------------------------------

The AmpC disk test was performed as described by Black *et al.* ([@R13]). In brief, the surface of a Mueller-Hinton agar plate was inoculated with a lawn of the cefoxitin (FOX) susceptible (*E. coli* ATCC 25922) according to the standard disk diffusion method. A FOX (30μg) disk was placed on the bacterial lawn on the surface of the Mueller-Hinton agar and flanked by two blank disks, each containing 20 μl of a 1:1 mixture of saline and 100X Tris-EDTA solution. Colonies of the test strain and control strains were applied to blank disks ([Fig.1](#F1){ref-type="fig"}). Flattening or indentation of the growth inhibition zone of the FOX disk at the side of blank disks containing the test strain indicated the release of AmpC-β-lactamase.

Statistical analysis {#S7}
--------------------

Statistical analysis were carried out using SPSS 15 statistical software.

Detection of AmpC overproduction {#S8}
--------------------------------

AmpC overproduction confirmed according was to the method described by Rodriguez-Martinez *et al.* ([@R7]). The isolates were considering as AmpC overproducer when there was at least a twofold dilution difference between the MICs of imipenem (IMI) or ceftazidime (CAZ) and the MICs of IMI or CAZ plus cloxacillin (COL).

RESULTS {#S9}
=======

During the study, a total of 100 clinical isolates of *P. aeruginosa* resistance to carbapenems (imipenem, meropenem or ertapenem) were collected from different burn patients who were admitted at Shahid Motahari Hospital of Tehran University of Medical Sciences. Susceptibility results and MICs are shown in [Table 1](#T1){ref-type="table"}. Seventy carbapenem-resistant *P. aeruginosa* with MICs ≥32μg/ml for IMI were isolated from different patients. The MICs of CAZ against 70 isolates were ≥ 1024 μg/ml. Fifty two isolates showed a twofold or threefold dilution difference between the MICs of IMI or CAZ and the MICs of IMI or CAZ plus COL. MICs to imipenem and ceftazidime in AmpC overproduction isolates of *P. aeruginosa* with/without cloxacillin are shown in [Table 2](#T2){ref-type="table"}. The prevalence of AmpC-β-lactamases producers by three phenotypic methods is shown in [Table 3](#T3){ref-type="table"}. Fifty four isolates were recognized as AmpC producers in AmpC disk test ([Fig. 1](#F1){ref-type="fig"}). Seventeen isolates showed AmpC-β-lactamases activity in combined disk method ([Fig. 2](#F2){ref-type="fig"}). One isolate was identified as AmpC-β-lactamases producer using three methods. Three isolates were AmpC producer as shown by both AmpC disk test and combined disk methods and 19 isolates demostrated AmpC activity by both AmpC disk test and MIC methods. Six isolates were proved to be AmpC producer as determined by MICs of IMI and CAZ.

DISCUSSION {#S10}
==========

In this study, AmpC disk test method identified 54 isolates as AmpC producer and combined disk method identified 17 isolates as AmpC producer. This result shows a probable activation of one of the efflux pumps system and impermeability, or both, against β-lactam antibiotics which causes falsely negative results in AmpC-β-lactamase detections in combined disk method. Resistance to cefoxitin is suggestive of an AmpC enzyme, but it is not specific since cefoxitin resistance can also be produced by certain carbapenemases and a few class A β -lactamases and by decreased levels of production of outer membrane porins ([@R1]). AmpC-β-lactamase not only cause hydrolysis and resistance to broad spectrum cephalosporins, aztreonam and cephamycins, but also cause hydrolysis of carbapenems and increase resistance to these antibiotics. Carbapenem resistant *P. aeruginosa* due to AmpC overproduction have been reported in many countries ([@R7],[@R14]). Lee and Rodriguez *et al.*, reported that AmpC-β-lactamase causes an increase of MIC to carbapenems, aztreonam and cephalosporins among 47% and 87% clinical *P. aeruginosa* isolates, respectively ([@R7],[@R14]). They reported that 51% of carbapenem-resistant clinical isolates of *P. aeruginosa* in their study overproduced AmpC-β-lactamase ([@R15]). In the present study, MICs of IMI and CAZ among 52 isolates reduced after adding cloxacillin, suggesting that the main mechanism associated with susceptibility reduction or resistance to imipenem was probably overexpression of AmpC and could therefore play an additive role in susceptibility reduction or resistance to imipenem. However, literatures suggested that AmpC-β-lactamase alone does not responsible for carbapenem resistant but could certainly increase the minimum inhibitory concentrations to β-lactamas antibiotics such as carbapenems and usually coupled with other mechanism specially loss of OprD porin ([@R4], [@R16]). It seems that the mechanisms leading to carbapenem resistance in Iran are more complex and are very likely multifactorial, involving overproduction of AmpC or Metallo-β-Lactamases ([@R8]-[@R10]). The simultaneous presence of these mechanisms of resistance causes an overlap and concealing of their resistance rates and therefore the interpretation of the phenotype appointing the relevant methods would be difficult. It also causes the increase of MICs in comparison with beta-lactam antibiotics resulting in a defeat of the remedy of infections with β-lactam antibiotics ([@R1],[@R5]).

In conclusion, results of this study, showed that AmpC-β-lactamases are responsible for decreasing the susceptibility of *P. aeruginosa* to different classes of β-lactam antibiotics in this region of Iran. A phenotypic test alone can not detect AmpC-β-lactamase-producing isolates. It highlights the necessity of different phenotypic methods for identification of AmpC-β-lactamase producing isolates among *P. aeruginosa* strains.
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###### 

Susceptibility of clinical isolates of *P. aeruginosa*.

  Antibacterial agents   Susceptible (n)   Intermediately susceptible (n)   Resistant (n)   MIC~50~(μg/ml)   MIC~90~(μg/ml)
  ---------------------- ----------------- -------------------------------- --------------- ---------------- ----------------
  IMI                    0                 0                                100             64               64
  CAZ                    16                0                                84              4096≤            4096≤
  MEM                    5                 8                                87              ND               ND
  ETP                    0                 0                                100             ND               ND
  CPM                    2                 0                                98              ND               ND
  CTX                    0                 0                                100             ND               ND
  FOX                    0                 0                                100             ND               ND

MEM: Meropenem, IMP: Imipenem, ETP: Ertapenem, CTX: Cefotaxime, CAZ: Ceftazidime, CPM: Cefepime, FOX: Cefoxitin.

ND: No determined.

###### 

MICs to imipenem and ceftazidime for AmpC overproduction isolates of *P. aeruginosa* whit/whitout cloxacillin.

  No. of Isolates   MIC (μg/ml)     No. of Isolates   MIC (μg/ml)          
  ----------------- --------------- ----------------- ------------- ------ ------
  19                64              16                5             4096   1024
  5                 128             32                2             2048   512
  10                32              8                 1             2048   256
  3                 64              8                 1             1024   256
  3                 32              4                 1             256    64
  5                 16              4                 1             128    32
  \-\-\-\-\-\--     \-\-\-\-\-\--   \-\-\-\-\-\--     1             64     16
  \-\-\-\-\-\--     \-\-\-\-\-\--   \-\-\-\-\-\--     1             16     4

CAZ: ceftazidime, CAZ-CLO: ceftazidime-cloxacillin, IMI: imipenem, IMI-CLO: imipenem-cloxacillin.

###### 

Prevalence of AmpC phenotype by different methods in carbapenem resistant *P. aeruginosa* isolates

  CTX+BA   CAZ+BA   CPM+BA   AmpC CAZ/COL   AmpC IMI/COL   AmpCdisk test   No. of Isolates
  -------- -------- -------- -------------- -------------- --------------- -----------------
  \-       \-       \+       \-             \-             \-              1
  \-       \-       \+       \-             \-             \+              1
  \-       \+       \+       \-             \+             \-              1
  \-       \+       \+       \-             \-             \+              1
  \+       \-       \+       \-             \-             \+              1
  \-       \+       \+       \-             \+             \+              1
  \-       \+       \-       \+             \+             \-              1
  \-       \+       \-       \-             \+             \-              1
  \+       \+       \+       \+             \-             \-              1
  \+       \+       \+       \-             \-             \-              1
  \+       \-       \-       \-             \+             \-              2
  \-       \-       \-       \+             \+             \-              2
  \-       \-       \-       \+             \+             \+              3
  \-       \-       \-       \+             \-             \+              3
  \-       \-       \-       \+             \-             \-              4
  \-       \-       \+       \-             \+             \-              5
  \-       \-       \-       \-             \+             \-              12
  \-       \-       \-       \-             \+             \+              16
  \-       \-       \-       \-             \-             \+              28

BA: Phenylboronic acid, CTX: Cefotaxime, CAZ: Ceftazidime, CPM: Cefepime, IMI: Imipenem, COL: Cloxacillin
